Buy Rating for Liquidia Technologies Driven by Promising YUTREPIA Launch and Favorable Competitive and Legal Landscape

Analyst Julian Harrison from BTIG maintained a Buy rating on Liquidia Technologies (LQDA – Research Report) and keeping the price target at $45.00.

Julian Harrison has given his Buy rating due to a combination of factors surrounding Liquidia Technologies. One key reason is the promising launch of YUTREPIA, which the management has described as progressing well, with expectations of profitability within three to four quarters. This optimism is supported by the company’s guidance on cost of goods sold and operational expenses, which suggests that YUTREPIA could become non-GAAP profitable once it reaches a certain threshold of payor-reimbursed patients.
Additionally, Harrison notes the competitive landscape, where Liquidia’s YUTREPIA could overshadow potential competitors like INSM’s TPIP, which faces challenges in its Phase 2b trials and expected difficulties in pivotal development. The legal landscape also appears favorable for Liquidia, as a recent court decision denied a preliminary injunction request against them, bolstering confidence in their ongoing patent litigation. These elements combined with a strategic valuation analysis contribute to the Buy rating for Liquidia Technologies.

In another report released on June 13, Raymond James also maintained a Buy rating on the stock with a $33.00 price target.

LQDA’s price has also changed moderately for the past six months – from $11.030 to $14.090, which is a 27.74% increase.